<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1004" relname="span">Extracellular vesicles</segment>
<segment id="3" parent="2" relname="elaboration">( EVs )</segment>
<segment id="4" parent="1003" relname="same_unit">are cell-derived membrane vesicles</segment>
<segment id="5" parent="1003" relname="elaboration">that represent an endogenous mechanism for intercellular communication .</segment>
<segment id="6" parent="1007" relname="span">EVs can be classified in exosomes , nano-sized vesicles</segment>
<segment id="7" parent="6" relname="elaboration">( with a diameter in the range of 30 to 120 nm ) ,</segment>
<segment id="8" parent="1008" relname="span">that originate from the cell endocytic compartment through the formation of multivesicular bodies</segment>
<segment id="9" parent="8" relname="elaboration">( MVB ) ,</segment>
<segment id="10" parent="1011" relname="span">microvesicles , with a diameter up to 1 μm</segment>
<segment id="11" parent="10" relname="elaboration">released by cell membrane budding , and apoptotic bodies , with a dimension similar to platelets ,</segment>
<segment id="12" parent="1011" relname="elaboration">derived from blebbing of dying cells .</segment>
<segment id="13" parent="1013" relname="span">Despite the distinct sizes and biogenesis , the absence of standardized isolation methods and the numerous similarities</segment>
<segment id="14" parent="13" relname="elaboration">existing between these two subclasses make it particularly challenging to distinguish among them .</segment>
<segment id="15" parent="1015" relname="span">In this review , we will use the generic term EVs</segment>
<segment id="16" parent="15" relname="purpose">to indicate both exosomes and microvesicles .</segment>
<segment id="17" parent="1017" relname="span">EVs have been shown to carry functionally active biological materials including proteins , mRNAs and miRNAs ,</segment>
<segment id="18" parent="17" relname="elaboration">which makes them capable of transmitting signals to target cells in the surrounding environment as well as to distant organs , via blood and lymphatic vessels .</segment>
<segment id="19" parent="1019" relname="preparation">The scientific community has recently turned its interest toward the evaluation of EVs as drug delivery vehicles .</segment>
<segment id="20" parent="1020" relname="preparation">In this context , EVs offer significant advantages over current drug delivery systems , such as liposomes and polymeric nanoparticles .</segment>
<segment id="21" parent="1023" relname="circumstance">Since EVs can be obtained with an autologous procedure from the patient ’s cells or blood ,</segment>
<segment id="22" parent="1023" relname="span">they do not solicit the immune system</segment>
<segment id="23" parent="22" relname="circumstance">as usual synthetic formulations do .</segment>
<segment id="24" parent="1024" relname="span">In addition ,</segment>
<segment id="25" parent="1026" relname="circumstance">given their phospholipid bilayer ,</segment>
<segment id="26" parent="1026" relname="span">EVs can directly fuse with the targeted plasma membrane ,</segment>
<segment id="27" parent="1027" relname="span">thus allowing a more efficient internalization of the encapsulated drug .</segment>
<segment id="28" parent="1030" relname="span">Their hydrophilic shell , together with the presence of anti-phagocytosis surface markers</segment>
<segment id="29" parent="28" relname="elaboration">( i. e. , CD47 ) ,</segment>
<segment id="30" parent="1029" relname="same_unit">enables them to evade phagocytosis by monocytes and macrophages of the reticulo-endothelial system ,</segment>
<segment id="31" parent="1028" relname="same_unit">hence weakening their clearance .</segment>
<segment id="32" parent="1031" relname="joint">Moreover , the limited size allows them to efficiently extravasate through the inter-endothelial junctions and fenestrations of both existing and neo-synthesized vessels .</segment>
<segment id="33" parent="34" relname="condition">Thanks to these peculiar characteristics ,</segment>
<segment id="34" parent="1033" relname="span">they can spread and accumulate in the parenchyma of solid tumors .</segment>
<segment id="35" parent="1035" relname="span">EV biological properties derive from their sophisticated membrane structure ,</segment>
<segment id="36" parent="1036" relname="span">characterized by the presence of several proteins for active targeting , adhesion , cell fusion , and intracellular release of their content ;</segment>
<segment id="37" parent="36" relname="elaboration">this functional complexity is not easily reproduced by de novo synthesized nanoparticles .</segment>
<segment id="38" parent="1039" relname="condition">Among the several types of nano-based drug delivery systems , liposomes are probably the most used ,</segment>
<segment id="39" parent="1039" relname="span">due to their non-toxicity and capacity</segment>
<segment id="40" parent="39" relname="purpose">to accommodate high amounts of compounds .</segment>
<segment id="41" parent="1041" relname="span">However , a still inadequate in vivo targeting efficiency together with a potential immunogenicity</segment>
<segment id="42" parent="41" relname="elaboration">associated to liposomal formulations has limited their broad applicability in therapeutics .</segment>
<segment id="43" parent="1043" relname="span">Therefore , the greater specificity</segment>
<segment id="44" parent="43" relname="elaboration">combined with the consequent limited induction of systemic side effects make EVs ideal vehicles for drug delivery .</segment>
<segment id="45" parent="46" relname="concession">Although this research field is in its infancy ,</segment>
<segment id="46" parent="1045" relname="span">in the last decade , the use of bio-engineered EVs for the delivery of cytotoxic molecules in preclinical models has produced encouraging results .</segment>
<segment id="47" parent="1047" relname="attribution">These experimental evidences , in addition to preliminary clinical data , indicate</segment>
<segment id="48" parent="1047" relname="joint">that EV formulations may not only enhance the safety and biodistribution of commonly used drugs ,</segment>
<segment id="49" parent="1048" relname="span">but also increase their efficacy .</segment>
<segment id="50" parent="1051" relname="attribution">For example , it has been demonstrated</segment>
<segment id="51" parent="1051" relname="span">that the administration of EV-encapsulating chemotherapy drugs leads to a significant reduction of drug accumulation in off-target organs ,</segment>
<segment id="52" parent="51" relname="elaboration">thus preventing important side effects during standard clinical protocols .</segment>
<segment id="53" parent="1052" relname="span">An astonishing number of newly published papers perfectly depict the scientific community ’s authentic interest in this flourishing research field .</segment>
<segment id="54" parent="1054" relname="span">Nevertheless , the first aim of this review is to disclose an overview of the latest applications of EVs as drug delivery vehicles ,</segment>
<segment id="55" parent="1056" relname="span">focusing on the sources</segment>
<segment id="56" parent="55" relname="elaboration">employed ,</segment>
<segment id="57" parent="1057" relname="span">the molecules</segment>
<segment id="58" parent="57" relname="elaboration">selected , and the final intended targets .</segment>
<segment id="59" parent="1058" relname="joint">In the second part of the review , we will take a step back</segment>
<segment id="60" parent="61" relname="preparation">and bring attention to the basics of one of the main pitfalls concerning EVs :</segment>
<segment id="61" parent="1059" relname="span">the urgent need for highly pure vesicle preparation .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="joint"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1006" type="span" parent="1001" relname="joint"/>
<group id="1007" type="span" parent="1006" relname="span"/>
<group id="1008" type="span" parent="1007" relname="elaboration"/>
<group id="1010" type="span" parent="1001" relname="joint"/>
<group id="1011" type="span" parent="1010" relname="span"/>
<group id="1012" type="span" parent="1001" relname="joint"/>
<group id="1013" type="span" parent="1012" relname="span"/>
<group id="1014" type="multinuc" parent="1013" relname="elaboration"/>
<group id="1015" type="span" parent="1014" relname="joint"/>
<group id="1016" type="span" parent="1014" relname="joint"/>
<group id="1017" type="span" parent="1018" relname="preparation"/>
<group id="1018" type="span" parent="1016" relname="span"/>
<group id="1019" type="span" parent="1018" relname="span"/>
<group id="1020" type="multinuc" parent="1019" relname="span"/>
<group id="1021" type="multinuc" parent="1020" relname="joint"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="span"/>
<group id="1024" type="span" parent="1021" relname="joint"/>
<group id="1025" type="span" parent="24" relname="elaboration"/>
<group id="1026" type="span" parent="1025" relname="span"/>
<group id="1027" type="span" parent="26" relname="elaboration"/>
<group id="1028" type="multinuc" parent="27" relname="elaboration"/>
<group id="1029" type="multinuc" parent="1028" relname="same_unit"/>
<group id="1030" type="span" parent="1029" relname="same_unit"/>
<group id="1031" type="multinuc" parent="1020" relname="joint"/>
<group id="1032" type="multinuc" parent="1031" relname="joint"/>
<group id="1033" type="span" parent="1032" relname="joint"/>
<group id="1034" type="multinuc" parent="1032" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="joint"/>
<group id="1036" type="span" parent="35" relname="elaboration"/>
<group id="1037" type="multinuc" parent="1034" relname="joint"/>
<group id="1038" type="span" parent="1037" relname="joint"/>
<group id="1039" type="span" parent="1038" relname="span"/>
<group id="1040" type="multinuc" parent="1037" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="joint"/>
<group id="1042" type="multinuc" parent="1040" relname="joint"/>
<group id="1043" type="span" parent="1042" relname="joint"/>
<group id="1044" type="span" parent="1042" relname="joint"/>
<group id="1045" type="span" parent="1044" relname="span"/>
<group id="1046" type="span" parent="1045" relname="elaboration"/>
<group id="1047" type="multinuc" parent="1046" relname="span"/>
<group id="1048" type="span" parent="1047" relname="joint"/>
<group id="1049" type="multinuc" parent="49" relname="elaboration"/>
<group id="1050" type="span" parent="1049" relname="joint"/>
<group id="1051" type="span" parent="1050" relname="span"/>
<group id="1052" type="span" parent="1049" relname="joint"/>
<group id="1053" type="span" parent="53" relname="elaboration"/>
<group id="1054" type="span" parent="1053" relname="span"/>
<group id="1055" type="multinuc" parent="54" relname="elaboration"/>
<group id="1056" type="span" parent="1055" relname="same_unit"/>
<group id="1057" type="span" parent="1055" relname="same_unit"/>
<group id="1058" type="multinuc" parent="1054" relname="elaboration"/>
<group id="1059" type="span" parent="1058" relname="joint"/>
	</body>
</rst>
